FDA Approves First mRNA Influenza Vaccine, Developed by Moderna
The approval of mFlusiva marks the regulatory expansion of mRNA platform technology beyond COVID-19 applications, with implications for federal vaccine procurement and public health policy.
The U.S. Food and Drug Administration on Wednesday, August 6, 2026, approved mFlusiva, the first influenza vaccine in the United States to use messenger RNA technology, according to reporting by NBC News and The New York Times. The vaccine was developed by Moderna, the Cambridge, Massachusetts-based pharmaceutical company that previously received FDA authorization for its mRNA-based COVID-19 vaccines.
The approval follows a notable procedural history. According to The New York Times, the FDA initially declined to accept Moderna's application for review, then reversed that decision following public comment. The agency's reversal and subsequent approval were processed under standard biologics licensing authority granted to the FDA under the Public Health Service Act (42 U.S.C. § 262). The specific review timeline, clinical trial data summary, and labeling conditions are contained in the FDA's Biologics License Application approval letter, which is publicly accessible through the FDA's Purple Book database.
Moderna is a publicly traded company (NASDAQ: MRNA) and a registered federal contractor. Its lobbying disclosures filed under the Lobbying Disclosure Act are publicly available through the Senate Office of Public Records. The company's political action committee and individual executive contribution records are searchable through FEC.gov. A full accounting of Moderna's federal lobbying expenditures and any related congressional contacts during the mFlusiva review period would be found in its quarterly LDA filings.
The federal government is a significant purchaser of influenza vaccines through agencies including the Centers for Disease Control and Prevention, which administers the Vaccines for Children program, and the Department of Defense. USASpending.gov contract records would reflect any procurement agreements between federal agencies and Moderna, though no such contract for mFlusiva has been publicly reported as of the date of this story.
Several material facts remain unknown at publication. The FDA has not yet publicly released the full clinical efficacy and safety data package submitted by Moderna, the specific populations for which mFlusiva is indicated, or the per-dose pricing agreed upon for any federal procurement. Those details would be disclosed in the FDA product label, the Biologics License Application summary, and any USASpending.gov contract awards once executed.